BACKGROUND: Fabry disease (FD) is a genetic disorder characterized by accumulation of trihexosylceramide in lysosomes of various tissues leading to multiorgan manifestations, including progressive renal disease. Previous screening studies have shown that a non-neglectable proportion of haemodialysis(HD) patients have unsuspected FD. An extensive FD screening study, the largest to date, has been conducted in HD patients in Czech Republic. We aimed to uncover previously undiagnosed FD patients, to enable them to benefit from cause-specific therapeutic intervention with enzyme replacement therapy (ERT). METHODS: Large-scale screening was executed using a convenient automated enzymatic (alpha-galactosidose A, alpha-Gal A) dried blood spot on filter paper fluorescence method. RESULTS: In total, 3370 (45.1% males, 54.9% females) out of 4058 HD patients (83%) in Czech Republic participated in this blood spot screening (BSS) study. Abnormal low fluorescence readings were obtained in 117 patients (3.5%). Subsequent determination of plasma alpha-Gal A activity identified four males and three females with deficient plasma enzyme activity. Determination of alpha-Gal A activity in peripheral blood leucocytes and confirmatory molecular analysis resulted in four newly diagnosed Fabry males and one female. Subsequent family screening identified 10 family members with genotypically proven FD. Based on these screening results, ERT could be offered to five male FD patients. CONCLUSIONS: BSS represents a promising screening tool that has proven to be convenient and effective in uncovering unrecognized FD patients among the chronic HD population in Czech Republic.

Department of Nephrology 1st Medical Faculty of Charles University and General Faculty Hospital Prague Czech Republic

000      

00000naa 2200000 a 4500

001      

bmc10006982

003      

CZ-PrNML

005      

20121220223156.0

008      

100324s2007 xxk e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Merta, Miroslav, $7 mzk2004248662 $d 1954-

245    12

$a A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population / $c Merta M., Reiterova J., Ledvinova J., Poupetová H., Dobrovolny R., Rysavá R., Maixnerová D., Bultas J., Motán J., Slivkova J., Sobotova D., Smrzova J., Tesar V.

314    __

$a Department of Nephrology, 1st Medical Faculty of Charles University and General Faculty Hospital, Prague, Czech Republic. merta@cesnet.cz

520    9_

$a BACKGROUND: Fabry disease (FD) is a genetic disorder characterized by accumulation of trihexosylceramide in lysosomes of various tissues leading to multiorgan manifestations, including progressive renal disease. Previous screening studies have shown that a non-neglectable proportion of haemodialysis(HD) patients have unsuspected FD. An extensive FD screening study, the largest to date, has been conducted in HD patients in Czech Republic. We aimed to uncover previously undiagnosed FD patients, to enable them to benefit from cause-specific therapeutic intervention with enzyme replacement therapy (ERT). METHODS: Large-scale screening was executed using a convenient automated enzymatic (alpha-galactosidose A, alpha-Gal A) dried blood spot on filter paper fluorescence method. RESULTS: In total, 3370 (45.1% males, 54.9% females) out of 4058 HD patients (83%) in Czech Republic participated in this blood spot screening (BSS) study. Abnormal low fluorescence readings were obtained in 117 patients (3.5%). Subsequent determination of plasma alpha-Gal A activity identified four males and three females with deficient plasma enzyme activity. Determination of alpha-Gal A activity in peripheral blood leucocytes and confirmatory molecular analysis resulted in four newly diagnosed Fabry males and one female. Subsequent family screening identified 10 family members with genotypically proven FD. Based on these screening results, ERT could be offered to five male FD patients. CONCLUSIONS: BSS represents a promising screening tool that has proven to be convenient and effective in uncovering unrecognized FD patients among the chronic HD population in Czech Republic.

650    _2

$a financování organizované $7 D005381

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé $7 D006801

650    _2

$a enzymy $x terapeutické užití $7 D004798

650    _2

$a Fabryho nemoc $x diagnóza $x krev $x terapie $7 D000795

650    _2

$a lyzozomy $x metabolismus $7 D008247

650    _2

$a lidé středního věku $7 D008875

650    _2

$a rodokmen $7 D010375

650    _2

$a konformace proteinů $7 D011487

650    _2

$a dialýza ledvin $x metody $7 D006435

650    _2

$a fluorescenční spektrometrie $7 D013050

650    _2

$a alfa-galaktosidasa $x chemie $7 D000519

651    _2

$a Česká republika $7 D018153

700    1_

$a Reiterová, Jana $7 xx0018667

700    1_

$a Ledvinová, Jana, $d 1943- $7 jo2003163160

700    1_

$a Poupětová, Helena, $d 1956- $7 jo2003181497

700    1_

$a Dobrovolný, Robert $7 xx0063743

700    1_

$a Ryšavá, Romana, $d 1967- $7 xx0084071

700    1_

$a Maixnerová, Dita $7 xx0063141

700    1_

$a Bultas, Jan, $d 1948- $7 nlk19990073058

700    1_

$a Motáň, Jiří, $d 1942- $7 nlk20030127976

700    1_

$a Slivková, Jitka $7 xx0115770

700    1_

$a Sobotová, Doris, $d 1945- $7 mzk2005271811

700    1_

$a Smržová, Jana, $d 1972- $7 xx0121636

700    1_

$a Tesař, Vladimír, $d 1957- $7 jn20000402349

773    0_

$w MED00010288 $t Nephrology, dialysis, transplantation $g Roč. 22, č. 1 (2007), s. 179-186 $x 0931-0509

910    __

$a ABA008 $b x $y 8

990    __

$a 20100114162108 $b ABA008

991    __

$a 20121220223251 $b ABA008

999    __

$a ok $b bmc $g 716626 $s 579629

BAS    __

$a 3

BMC    __

$a 2007 $b 22 $c 1 $d 179-186 $i 0931-0509 $m Nephrology, dialysis, transplantation $x MED00010288

LZP    __

$a 2010-b1/dkme